The source belongs next to the claim.
Here's where the explanations lead: research papers, medicine labels and FDA pages. Each note says what the source adds. Follow the question that interests you; there's no need to read the whole shelf. These sources explain research and products, not a personal treatment plan.
Tesamorelin in adults with HIV and abdominal fat accumulation
Falutz and colleagues, 2007. The trial measured fat around the organs in adults with HIV. Its result belongs to that group.
Read the sourceWhat happened during continued tesamorelin treatment and after stopping
Falutz and colleagues, 2008. In adults with HIV and extra abdominal fat, the reduction in fat around the organs held during treatment; fat built up again after stopping.
Read the sourceTesamorelin prescribing information (Egrifta WR)
The U.S. label gives the HIV-related approved use, safety warnings and monitoring. It says tesamorelin isn't for weight-loss management.
Read the sourceSTEP 1 and semaglutide in adults without diabetes
Wilding and colleagues, 2021. Adults had obesity, or overweight with a weight-related condition, without diabetes. This is the injected semaglutide study discussed here.
Read the sourceA review of semaglutide safety
Smits and Van Raalte, 2021. The review covers stomach and bowel effects and gallbladder concerns. Those belong beside the weight findings.
Read the sourceWegovy prescribing information for semaglutide
The U.S. label covers forms, uses and warnings. Thyroid tumors were seen in rodents; whether semaglutide causes them in people is unknown.
Read the sourceSURMOUNT-1 and assigned tirzepatide amounts
Jastreboff and colleagues, 2022. Different tirzepatide groups had different average weight losses. The study doesn't pick an amount for an individual.
Read the sourceTirzepatide, pancreatitis and gallbladder or biliary disease
Zeng and colleagues, 2023. This review examined pancreatitis and gallbladder or bile-duct problems. Its uncertain pancreatitis estimate cannot rule out increased risk.
Read the sourceZepbound prescribing information for tirzepatide
The U.S. label sets out uses and warnings, including thyroid tumors seen in rats. The relevance to people remains unknown.
Read the sourceIpamorelin blood levels and hormone response in healthy men
Gobburu and colleagues, 1999. Infusions into a vein in healthy men produced a short hormone pulse. This wasn't a sleep or recovery test.
Read the sourceIpamorelin after bowel surgery
Beck and colleagues, 2014. After bowel surgery, the trial didn't establish a clear benefit on its main measure: tolerating a meal sooner.
Read the sourceFDA's assessment of ipamorelin-related substances
FDA's 2024 assessment discusses evidence gaps and serious events in the surgery trial. It doesn't establish that ipamorelin caused the deaths.
Read the sourceFDA's bulk-substance safety concerns
On this page current as of April 22, 2026, ipamorelin acetate appears in 503B Category 2 and among withdrawn nominations. Withdrawal isn't clearance.
Read the sourceFDA explains compounded medicines
FDA explains why compounded drugs are not FDA-approved. An approved ingredient name doesn't give every preparation the approval of a manufactured medicine.
Read the sourceFDA's concerns about unapproved GLP-1 drugs
FDA describes risks with unapproved semaglutide and tirzepatide, including dosing errors. Its advice points to prescriptions and state-licensed pharmacies.
Read the source